Semaglutide manufacturers seem to be taking advantage of America’s health crises to indulge in anticompetitive behavior.

China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

These can include weight loss, loss of appetite, yellowing of the skin, vomiting or nausea, and the symptoms of diabetes ...

For CVS Health CVS, the key to building customer trust is to enhance access to life-changing medications and also make them affordable. Beginning July 1, the company’s Pharmacy Benefit Manager (“PBM”) ...

Novo Nordisk just killed its deal with Hims & Hers. But Hims might come out stronger after this development. Read why the ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” ...

Novo Nordisk A/S and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

Hims & Hers extended its rally for the second day on Friday, adding 6.76 percent to close at $49.41 apiece after its chief ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...